ArticleDrug and alcohol dependence2015
Self-reported use of novel psychoactive substances in a US nationally representative survey: Prevalence, correlates, and a call for new survey methods to prevent underreporting.
Article in Drug and alcohol dependence, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 172 citations in OpenAlex.
- Assessing self-reported use of new psychoactive substances: The impact of gate questions.The American journal of drug and alcohol abuse · 2017Trial
- Epidemiology of Hallucinogen Microdosing Among Young Adults in the United States: A National Study.Drug and alcohol review · 2026Article
- Self-Reported Adverse Effects Associated With New Psychoactive Substance Use in a Sample of Adults From 20 US Cities.Drug and alcohol review · 2026Article
- Prevalence and correlates of self-reported new psychoactive substance use among adults in 20 US cities: Results from National Drug Early Warning System surveillance.Drug and alcohol dependence · 2025Article
- Two Drug Epidemics in St. Petersburg, Russia? Substance Use, Risk Behaviors, and HIV and HCV Prevalence Among Young and Older People Who Inject Drugs Attending a Harm Reduction Facility.AIDS and behavior · 2025Article
- Synthetic cannabinoid use among noninstitutionalized individuals in the United States, 2021-2023.Drug and alcohol dependence · 2025Article
- Bath salt use in the military: Experiences with synthetic cathinone use among justice-involved Veterans.Journal of military, veteran and family health · 2024Article
- Monitoring illicit pentobarbital availability in the United States: A National Drug Early Warning System briefing.Drug and alcohol dependence · 2024Article
- Article
- Infoveillance and Critical Analysis of the Systematically Reviewed Literature on Dimethyltryptamine and the "God Molecule".Pharmaceuticals (Basel, Switzerland) · 2023Review
- First results of the French OCTOPUS survey among festival attendees: a latent class analysis.Harm reduction journal · 2023Article
- Underreported drug use among dental patients: A call for dental care professionals to improve drug use screening.Journal of the American Dental Association (1939) · 2023Article
- Effects of repeated binge intake of the pyrovalerone cathinone derivative 3,4-methylenedioxypyrovalerone on prefrontal cytokine levels in rats - a preliminary study.Frontiers in behavioral neuroscience · 2023Article
- Associations between Oral Health and Cannabis Use among Adolescents and Young Adults: Implications for Orthodontists.International journal of environmental research and public health · 2022Article
- Validity between self-report and biochemical testing of cannabis and drugs among patients with traumatic injury: brief report.Journal of cannabis research · 2022Article
- Invited Commentary: Drug Checking for Novel Insights Into the Unregulated Drug Supply.American journal of epidemiology · 2022Article
- Kratom Use Is Underestimated, but Prevalence Still Appears to Be Low.American journal of preventive medicine · 2022Article
- Sex and Gender Differences in the Effects of Novel Psychoactive Substances.Brain sciences · 2020Review
- A qualitative descriptive analysis of effects of psychedelic phenethylamines and tryptamines.Human psychopharmacology · 2020Article
- Reinforcing Effects of the Synthetic Cathinone α-Pyrrolidinopropiophenone (α-PPP) in a Repeated Extended Access Binge Paradigm.Frontiers in psychiatry · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundIn recent years, there has been an increase in emergence and use of novel psychoactive substances (NPS) in the US and worldwide. However, there is little published epidemiological survey data estimating the prevalence of use in the US.
methodData on self-reported NPS use came from the National Survey of Drug Use and Health (2009-2013), a national representative sample of non-institutionalized individuals in the US. Subjects were asked to provide names of (non-traditional) drugs they used that they were not specifically asked about. We examined lifetime prevalence and sociodemographic correlates of self-reported use of new and uncommon synthetic drugs (NPS) among subjects ages 12-34-years-old.
results1.2% of subjects self-reported any use of the 57 NPS we examined. Use of psychedelic tryptamines (primarily DMT) was most common, followed by psychedelic phenethylamines (e.g., 2C series) and synthetic cannabinoids. Prevalence of self-reported use of NPS increased from 2009 to 2013 and use was most common among males, whites, older subjects, those of lower income, and among those residing in cities. Lifetime use of various other illicit drugs (e.g., LSD, cocaine, ecstasy/MDMA) was highly prevalent among NPS users.
conclusionThis the first study reporting on use of a variety of NPS in a nationally representative US sample; however, use appears to be underreported as other national data suggest higher rates of NPS (e.g., synthetic cannabinoid) use. Developing more adaptable survey tools and systematically assessing NPS use would allow researchers to ask about hundreds of NPS and improve reporting as new drugs continue to rapidly emerge.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.